BioFilm Control  : In vitro diagnostic tests to detect biofilm activity in chronic infections

The diagnostics for biofilm is performed by the BioFilm Control division.

We use our technologies to determine the existing antibiotic that is the best suited to fight a specific disease in the biofilm formation stage. This is called “antibiofilmogram.”

The antibiofilmogram enables us to deliver on-demand biofilm diagnostic services in regional diagnostics centers.

As of today, the first diagnostic test for chronic wound infections (Diabetic Foot Ulcer and Joint and Bones Infections) is in process of CE certification and comparative clinical trials have been successfully completed.

We are proud of these first clinical trials, which clearly demonstrate the usefulness of our discoveries in demanding and painful medical cases.

Our technology has also been shown to work in more common cases where the use of the antibiofilmogram makes a difference in the patient’s treatment.

Since 2016, BioFilm Control has been ISO certified, which is essential for CE certification and is a guarantee of quality and production control.

The anti-biofilm diagnostics has obtained CE Marking for Infected Wounds in 01/21, and the Respiratory Infections test will be CE Marked in 04/22.

Social Security reimbursement in France and Europe is targeted between Q3/23 and Q3/24.

US and rest of the world markets will be addressed via license agreements on our technology, starting 2023/2024.